Evoke Pharma, Inc. (EVOK) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1232415,
    "name": "Evoke Pharma, Inc.",
    "stock_name": "Evoke Pharma, Inc.",
    "full_name": "Evoke Pharma, Inc.",
    "name_url": "stocks-analysis/evoke-pharma-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "10.94",
    "chg": 0.03,
    "chgp": "0.27%",
    "dir": 1,
    "prev_price": "10.91",
    "mcapval": "8.10",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US30049G2030",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "19.13 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/evoke-pharma-inc-1232415-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Evoke Pharma, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-evoke-pharma-inc-technically-bullish-or-bearish-3547181",
        "imagepath": "",
        "date": "2025-09-20 19:48:57",
        "description": "As of 2 September 2025, the technical trend for Evoke Pharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and mildly bullish signals from both the Bollinger Bands and moving averages on the daily timeframe. However, the weekly RSI is bearish, and the Dow Theory indicates a mildly bearish trend. \n\nIn terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -1.93% and -14.77% respectively, while it has outperformed on a year-to-date and one-year basis with returns of 14.93% and 19.81%. Overall, the mixed signals suggest caution despite the mildly bullish trend...."
      },
      {
        "title": "Is Evoke Pharma, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-evoke-pharma-inc-overvalued-or-undervalued-3543608",
        "imagepath": "",
        "date": "2025-09-20 18:23:57",
        "description": "As of 10 November 2021, Evoke Pharma, Inc. has moved from a grade of does not qualify to risky. The company is currently overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 0.75, an EV to EBIT of 0.63, and an EV to EBITDA of 0.63, which indicate significant valuation concerns relative to its earnings and assets.\n\nIn comparison with its peers, Evoke Pharma's EV to EBITDA ratio of -0.2076 is notably worse than Agile Therapeutics, Inc. at -0.5982 and Bellerophon Therapeutics, Inc. at 0.4464, highlighting its underperformance in generating earnings relative to its enterprise value. Additionally, while the company has shown a YTD return of 14.93%, it has significantly lagged behind the S&P 500's 12.22% return, and its long-term performance is concerning with a 5Y return of -99.28%...."
      }
    ],
    "total": 7,
    "sid": "1232415",
    "stock_news_url": "https://www.marketsmojo.com/news/evoke-pharma-inc-1232415"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Evoke Pharma, Inc. technically bullish or bearish?

2025-09-20 19:48:57

As of 2 September 2025, the technical trend for Evoke Pharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and mildly bullish signals from both the Bollinger Bands and moving averages on the daily timeframe. However, the weekly RSI is bearish, and the Dow Theory indicates a mildly bearish trend. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -1.93% and -14.77% respectively, while it has outperformed on a year-to-date and one-year basis with returns of 14.93% and 19.81%. Overall, the mixed signals suggest caution despite the mildly bullish trend....

Is Evoke Pharma, Inc. overvalued or undervalued?

2025-09-20 18:23:57

As of 10 November 2021, Evoke Pharma, Inc. has moved from a grade of does not qualify to risky. The company is currently overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 0.75, an EV to EBIT of 0.63, and an EV to EBITDA of 0.63, which indicate significant valuation concerns relative to its earnings and assets. In comparison with its peers, Evoke Pharma's EV to EBITDA ratio of -0.2076 is notably worse than Agile Therapeutics, Inc. at -0.5982 and Bellerophon Therapeutics, Inc. at 0.4464, highlighting its underperformance in generating earnings relative to its enterprise value. Additionally, while the company has shown a YTD return of 14.93%, it has significantly lagged behind the S&P 500's 12.22% return, and its long-term performance is concerning with a 5Y return of -99.28%....

View All News